| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Panax | 57 | 2017 | 171 | 12.320 |
Why?
|
| Plant Extracts | 64 | 2017 | 247 | 11.070 |
Why?
|
| Phytotherapy | 42 | 2016 | 137 | 8.920 |
Why?
|
| Ginsenosides | 39 | 2016 | 124 | 8.180 |
Why?
|
| Antineoplastic Agents, Phytogenic | 25 | 2016 | 270 | 6.270 |
Why?
|
| Naltrexone | 24 | 2013 | 139 | 3.850 |
Why?
|
| Narcotic Antagonists | 24 | 2013 | 170 | 3.790 |
Why?
|
| Colorectal Neoplasms | 30 | 2014 | 1053 | 3.400 |
Why?
|
| Drugs, Chinese Herbal | 19 | 2015 | 68 | 3.160 |
Why?
|
| Chromatography, High Pressure Liquid | 23 | 2016 | 307 | 2.690 |
Why?
|
| Flavonoids | 12 | 2015 | 85 | 2.660 |
Why?
|
| Apoptosis | 34 | 2016 | 1721 | 2.580 |
Why?
|
| Panax notoginseng | 7 | 2016 | 23 | 2.510 |
Why?
|
| Cell Proliferation | 27 | 2015 | 1741 | 2.430 |
Why?
|
| Oplopanax | 7 | 2014 | 29 | 2.400 |
Why?
|
| Plant Roots | 28 | 2017 | 112 | 2.290 |
Why?
|
| Antioxidants | 13 | 2014 | 231 | 2.280 |
Why?
|
| Saponins | 13 | 2016 | 41 | 2.230 |
Why?
|
| Sapogenins | 7 | 2016 | 25 | 2.160 |
Why?
|
| Colonic Neoplasms | 8 | 2017 | 579 | 2.060 |
Why?
|
| Fruit | 13 | 2011 | 81 | 1.950 |
Why?
|
| Fluorouracil | 8 | 2015 | 524 | 1.860 |
Why?
|
| Cell Cycle | 19 | 2015 | 515 | 1.850 |
Why?
|
| Plants, Medicinal | 12 | 2014 | 39 | 1.740 |
Why?
|
| Hypoglycemic Agents | 12 | 2014 | 379 | 1.730 |
Why?
|
| Scutellaria baicalensis | 9 | 2015 | 26 | 1.610 |
Why?
|
| Analgesics, Opioid | 13 | 2013 | 513 | 1.540 |
Why?
|
| Animals | 92 | 2017 | 28155 | 1.420 |
Why?
|
| Flavanones | 8 | 2015 | 35 | 1.380 |
Why?
|
| Brain Stem | 11 | 2004 | 163 | 1.360 |
Why?
|
| Morphine | 11 | 2004 | 128 | 1.350 |
Why?
|
| Pica | 6 | 2007 | 14 | 1.340 |
Why?
|
| Mass Spectrometry | 4 | 2016 | 200 | 1.340 |
Why?
|
| Blood Glucose | 12 | 2014 | 867 | 1.250 |
Why?
|
| Vitis | 7 | 2011 | 19 | 1.240 |
Why?
|
| Myocytes, Cardiac | 8 | 2011 | 313 | 1.230 |
Why?
|
| Constipation | 7 | 2013 | 66 | 1.200 |
Why?
|
| Cell Line, Tumor | 29 | 2014 | 2755 | 1.200 |
Why?
|
| Anticarcinogenic Agents | 5 | 2013 | 71 | 1.200 |
Why?
|
| Solitary Nucleus | 11 | 2004 | 22 | 1.180 |
Why?
|
| Colitis | 4 | 2017 | 261 | 1.140 |
Why?
|
| Oxidative Stress | 9 | 2008 | 467 | 1.130 |
Why?
|
| Leptin | 6 | 2009 | 100 | 1.120 |
Why?
|
| Stomach | 9 | 2004 | 113 | 1.120 |
Why?
|
| HCT116 Cells | 15 | 2015 | 162 | 1.100 |
Why?
|
| Drug Synergism | 12 | 2015 | 315 | 1.090 |
Why?
|
| Quaternary Ammonium Compounds | 23 | 2013 | 81 | 1.050 |
Why?
|
| Plant Preparations | 3 | 2016 | 20 | 1.040 |
Why?
|
| Antineoplastic Agents | 13 | 2014 | 2303 | 1.000 |
Why?
|
| Antimetabolites, Antineoplastic | 4 | 2015 | 244 | 0.990 |
Why?
|
| Gastrointestinal Microbiome | 4 | 2017 | 590 | 0.970 |
Why?
|
| Biological Products | 4 | 2014 | 178 | 0.960 |
Why?
|
| Neurons | 10 | 2016 | 1582 | 0.940 |
Why?
|
| Gastrointestinal Transit | 9 | 2005 | 20 | 0.910 |
Why?
|
| Smilax | 2 | 2015 | 5 | 0.880 |
Why?
|
| Vomiting | 7 | 2012 | 108 | 0.870 |
Why?
|
| Carcinogenesis | 2 | 2017 | 235 | 0.870 |
Why?
|
| Mice | 32 | 2017 | 12269 | 0.870 |
Why?
|
| Cisplatin | 7 | 2006 | 568 | 0.860 |
Why?
|
| Hyperuricemia | 2 | 2015 | 25 | 0.850 |
Why?
|
| Dose-Response Relationship, Drug | 21 | 2013 | 1914 | 0.850 |
Why?
|
| Obesity | 8 | 2011 | 1018 | 0.840 |
Why?
|
| Chromatography, Liquid | 2 | 2016 | 104 | 0.820 |
Why?
|
| Humans | 98 | 2016 | 93515 | 0.810 |
Why?
|
| Neoplasms | 7 | 2016 | 3169 | 0.810 |
Why?
|
| Proanthocyanidins | 5 | 2011 | 12 | 0.760 |
Why?
|
| Rats | 25 | 2012 | 4072 | 0.750 |
Why?
|
| Nausea | 7 | 2012 | 93 | 0.740 |
Why?
|
| Narcotics | 5 | 2006 | 72 | 0.730 |
Why?
|
| Disease Models, Animal | 18 | 2016 | 2495 | 0.720 |
Why?
|
| Drug Contamination | 2 | 2014 | 12 | 0.720 |
Why?
|
| Reishi | 3 | 2007 | 7 | 0.720 |
Why?
|
| Reactive Oxygen Species | 13 | 2014 | 502 | 0.710 |
Why?
|
| Purkinje Fibers | 5 | 2001 | 27 | 0.700 |
Why?
|
| Rats, Sprague-Dawley | 17 | 2014 | 1245 | 0.670 |
Why?
|
| Diabetes Mellitus, Type 2 | 6 | 2011 | 1229 | 0.650 |
Why?
|
| Body Weight | 10 | 2013 | 449 | 0.640 |
Why?
|
| Gastrointestinal Motility | 4 | 2006 | 26 | 0.640 |
Why?
|
| Pain | 5 | 2004 | 414 | 0.640 |
Why?
|
| Free Radical Scavengers | 5 | 2013 | 59 | 0.620 |
Why?
|
| Breast Neoplasms | 6 | 2013 | 3110 | 0.620 |
Why?
|
| Injections, Intraperitoneal | 11 | 2011 | 102 | 0.610 |
Why?
|
| Oxidants | 6 | 2007 | 86 | 0.600 |
Why?
|
| Mice, Obese | 10 | 2011 | 49 | 0.580 |
Why?
|
| Male | 52 | 2017 | 44557 | 0.570 |
Why?
|
| Antiemetics | 5 | 2007 | 28 | 0.570 |
Why?
|
| Medicine, Chinese Traditional | 3 | 2012 | 9 | 0.560 |
Why?
|
| Reperfusion Injury | 2 | 2011 | 148 | 0.540 |
Why?
|
| Caspases | 5 | 2013 | 151 | 0.530 |
Why?
|
| Cell Survival | 12 | 2010 | 1004 | 0.530 |
Why?
|
| Diabetes Mellitus, Experimental | 3 | 2009 | 201 | 0.530 |
Why?
|
| Diynes | 2 | 2013 | 7 | 0.490 |
Why?
|
| Fatty Alcohols | 2 | 2013 | 10 | 0.490 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2016 | 109 | 0.490 |
Why?
|
| Dietary Supplements | 4 | 2005 | 131 | 0.480 |
Why?
|
| Herbal Medicine | 3 | 2012 | 8 | 0.480 |
Why?
|
| Phenols | 2 | 2006 | 41 | 0.480 |
Why?
|
| Azoxymethane | 4 | 2017 | 84 | 0.470 |
Why?
|
| Hydrogen Peroxide | 6 | 2008 | 164 | 0.470 |
Why?
|
| Hot Temperature | 4 | 2013 | 218 | 0.460 |
Why?
|
| Crocus | 2 | 2013 | 3 | 0.460 |
Why?
|
| Catechin | 2 | 2012 | 22 | 0.450 |
Why?
|
| Mice, Nude | 6 | 2015 | 824 | 0.450 |
Why?
|
| Dextran Sulfate | 4 | 2017 | 70 | 0.450 |
Why?
|
| Plant Leaves | 5 | 2006 | 86 | 0.450 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2014 | 25 | 0.440 |
Why?
|
| Allopurinol | 1 | 2015 | 77 | 0.430 |
Why?
|
| Animals, Newborn | 9 | 2009 | 522 | 0.430 |
Why?
|
| Cell Death | 3 | 2013 | 253 | 0.430 |
Why?
|
| Diabetes Mellitus | 5 | 2005 | 767 | 0.430 |
Why?
|
| Glycosides | 1 | 2014 | 21 | 0.430 |
Why?
|
| Uricosuric Agents | 1 | 2014 | 11 | 0.430 |
Why?
|
| Complementary Therapies | 3 | 2010 | 53 | 0.430 |
Why?
|
| Daphne | 1 | 2014 | 9 | 0.420 |
Why?
|
| Chick Embryo | 9 | 2009 | 222 | 0.420 |
Why?
|
| Glucose Tolerance Test | 8 | 2014 | 232 | 0.420 |
Why?
|
| NF-kappa B | 3 | 2014 | 408 | 0.420 |
Why?
|
| Vagus Nerve | 4 | 2004 | 45 | 0.420 |
Why?
|
| Arthritis, Experimental | 1 | 2014 | 26 | 0.410 |
Why?
|
| Membrane Potential, Mitochondrial | 3 | 2013 | 32 | 0.410 |
Why?
|
| Genistein | 1 | 2013 | 16 | 0.400 |
Why?
|
| Steroids | 1 | 2014 | 168 | 0.400 |
Why?
|
| Seeds | 5 | 2009 | 62 | 0.390 |
Why?
|
| Structure-Activity Relationship | 6 | 2016 | 422 | 0.390 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2013 | 64 | 0.380 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2013 | 454 | 0.380 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2015 | 526 | 0.380 |
Why?
|
| Bufanolides | 3 | 2001 | 5 | 0.370 |
Why?
|
| Rats, Wistar | 7 | 2007 | 300 | 0.370 |
Why?
|
| Plant Stems | 2 | 2009 | 9 | 0.360 |
Why?
|
| Mitochondria | 2 | 2013 | 612 | 0.360 |
Why?
|
| Chemoprevention | 4 | 2013 | 93 | 0.360 |
Why?
|
| Bile | 1 | 2012 | 60 | 0.360 |
Why?
|
| Herb-Drug Interactions | 1 | 2011 | 5 | 0.360 |
Why?
|
| Administration, Oral | 9 | 2011 | 657 | 0.360 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2015 | 2544 | 0.350 |
Why?
|
| Cold Temperature | 5 | 2004 | 159 | 0.350 |
Why?
|
| Cardiotonic Agents | 3 | 2001 | 88 | 0.350 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2014 | 353 | 0.340 |
Why?
|
| Molecular Structure | 5 | 2015 | 307 | 0.340 |
Why?
|
| Mice, Inbred C57BL | 10 | 2012 | 3435 | 0.340 |
Why?
|
| Camptothecin | 1 | 2012 | 196 | 0.330 |
Why?
|
| Methadone | 3 | 2000 | 51 | 0.330 |
Why?
|
| Publishing | 1 | 2012 | 91 | 0.330 |
Why?
|
| Flow Cytometry | 5 | 2010 | 712 | 0.330 |
Why?
|
| Cyclin A | 4 | 2013 | 27 | 0.320 |
Why?
|
| Antimycin A | 3 | 2006 | 13 | 0.310 |
Why?
|
| Drug Interactions | 7 | 2012 | 239 | 0.310 |
Why?
|
| Intra-Abdominal Fat | 1 | 2009 | 31 | 0.300 |
Why?
|
| Biological Availability | 3 | 2016 | 86 | 0.300 |
Why?
|
| Coronary Disease | 1 | 2011 | 223 | 0.300 |
Why?
|
| Gene Expression Profiling | 3 | 2014 | 1518 | 0.300 |
Why?
|
| Double-Blind Method | 10 | 2014 | 1729 | 0.300 |
Why?
|
| Araliaceae | 1 | 2009 | 2 | 0.300 |
Why?
|
| Adiposity | 1 | 2009 | 76 | 0.300 |
Why?
|
| Cells, Cultured | 9 | 2007 | 2850 | 0.300 |
Why?
|
| Signal Transduction | 4 | 2014 | 3502 | 0.290 |
Why?
|
| Antibodies, Monoclonal | 2 | 2014 | 1395 | 0.280 |
Why?
|
| Eating | 3 | 2009 | 162 | 0.280 |
Why?
|
| Weight Gain | 1 | 2009 | 128 | 0.280 |
Why?
|
| Gastric Emptying | 3 | 2008 | 26 | 0.280 |
Why?
|
| Female | 28 | 2014 | 48702 | 0.280 |
Why?
|
| Muscimol | 4 | 2004 | 18 | 0.280 |
Why?
|
| GABA Antagonists | 4 | 2004 | 26 | 0.280 |
Why?
|
| Baclofen | 3 | 2004 | 16 | 0.280 |
Why?
|
| Weight Loss | 1 | 2009 | 234 | 0.270 |
Why?
|
| Cell Division | 2 | 2006 | 693 | 0.270 |
Why?
|
| Heart | 2 | 2002 | 522 | 0.270 |
Why?
|
| HIV Protease Inhibitors | 1 | 2007 | 21 | 0.270 |
Why?
|
| Ritonavir | 1 | 2007 | 13 | 0.270 |
Why?
|
| Intestinal Mucosa | 3 | 2014 | 824 | 0.270 |
Why?
|
| Carotenoids | 1 | 2007 | 17 | 0.260 |
Why?
|
| Central Nervous System Agents | 3 | 2001 | 15 | 0.250 |
Why?
|
| Valerian | 2 | 2004 | 3 | 0.250 |
Why?
|
| Anti-Arrhythmia Agents | 3 | 2001 | 76 | 0.250 |
Why?
|
| Cholesterol | 2 | 2006 | 364 | 0.240 |
Why?
|
| Receptors, Opioid, mu | 2 | 2013 | 49 | 0.240 |
Why?
|
| Murraya | 1 | 2006 | 2 | 0.240 |
Why?
|
| Electrophysiology | 6 | 2004 | 390 | 0.240 |
Why?
|
| Kava | 2 | 2002 | 3 | 0.240 |
Why?
|
| Flowers | 3 | 2014 | 41 | 0.240 |
Why?
|
| Area Under Curve | 5 | 2005 | 335 | 0.240 |
Why?
|
| Drug Screening Assays, Antitumor | 4 | 2013 | 85 | 0.230 |
Why?
|
| Nitric Oxide | 4 | 2014 | 281 | 0.230 |
Why?
|
| Kaolin | 4 | 2007 | 9 | 0.230 |
Why?
|
| Adult | 21 | 2016 | 27918 | 0.220 |
Why?
|
| Platelet Activation | 1 | 2005 | 18 | 0.220 |
Why?
|
| Angelica | 1 | 2004 | 2 | 0.220 |
Why?
|
| Organic Anion Transport Protein 1 | 2 | 2015 | 4 | 0.220 |
Why?
|
| Corydalis | 1 | 2004 | 4 | 0.220 |
Why?
|
| Glucose Transport Proteins, Facilitative | 2 | 2015 | 8 | 0.220 |
Why?
|
| Strophanthidin | 2 | 2001 | 3 | 0.220 |
Why?
|
| Polyphenols | 3 | 2012 | 13 | 0.220 |
Why?
|
| Organic Anion Transporters | 2 | 2015 | 26 | 0.220 |
Why?
|
| Cell Cycle Checkpoints | 3 | 2013 | 68 | 0.220 |
Why?
|
| Blood Coagulation | 1 | 2005 | 90 | 0.210 |
Why?
|
| Gastrointestinal Diseases | 1 | 2006 | 149 | 0.210 |
Why?
|
| Cholecystokinin | 2 | 2002 | 15 | 0.210 |
Why?
|
| Digestive System | 2 | 2001 | 40 | 0.210 |
Why?
|
| Indenes | 1 | 2004 | 9 | 0.210 |
Why?
|
| Sesquiterpenes | 1 | 2004 | 13 | 0.210 |
Why?
|
| Mitochondria, Heart | 2 | 2002 | 48 | 0.210 |
Why?
|
| Uric Acid | 2 | 2015 | 137 | 0.210 |
Why?
|
| Receptors, GABA | 1 | 2004 | 11 | 0.210 |
Why?
|
| Ephedra sinica | 1 | 2004 | 1 | 0.210 |
Why?
|
| Scutellaria | 1 | 2004 | 3 | 0.210 |
Why?
|
| Insulin-Secreting Cells | 1 | 2008 | 441 | 0.210 |
Why?
|
| Warfarin | 1 | 2004 | 106 | 0.200 |
Why?
|
| Colon | 4 | 2013 | 540 | 0.200 |
Why?
|
| Gymnema | 1 | 2003 | 1 | 0.200 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2009 | 1133 | 0.200 |
Why?
|
| Risk | 3 | 2013 | 657 | 0.200 |
Why?
|
| G2 Phase Cell Cycle Checkpoints | 2 | 2013 | 14 | 0.200 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2004 | 74 | 0.190 |
Why?
|
| Heterografts | 2 | 2014 | 116 | 0.190 |
Why?
|
| Electroacupuncture | 1 | 2003 | 1 | 0.190 |
Why?
|
| Nucleus Accumbens | 1 | 2004 | 113 | 0.190 |
Why?
|
| Pyrones | 1 | 2002 | 8 | 0.190 |
Why?
|
| GABA Agents | 1 | 2002 | 8 | 0.190 |
Why?
|
| Myocardium | 3 | 2002 | 570 | 0.190 |
Why?
|
| Lactones | 1 | 2002 | 27 | 0.190 |
Why?
|
| Endoplasmic Reticulum Stress | 2 | 2014 | 91 | 0.190 |
Why?
|
| Gene Expression | 3 | 2013 | 1301 | 0.190 |
Why?
|
| Acupressure | 1 | 2002 | 1 | 0.190 |
Why?
|
| Pain Threshold | 1 | 2003 | 63 | 0.190 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2008 | 1338 | 0.190 |
Why?
|
| Transcutaneous Electric Nerve Stimulation | 1 | 2002 | 16 | 0.190 |
Why?
|
| Cell Hypoxia | 2 | 2002 | 187 | 0.190 |
Why?
|
| Galanin | 1 | 2002 | 4 | 0.190 |
Why?
|
| Digestive System Physiological Phenomena | 1 | 2002 | 4 | 0.190 |
Why?
|
| Receptors, Opioid | 2 | 2006 | 23 | 0.180 |
Why?
|
| China | 2 | 2014 | 264 | 0.180 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2001 | 225 | 0.180 |
Why?
|
| Breath Tests | 5 | 2002 | 58 | 0.180 |
Why?
|
| Anti-Obesity Agents | 1 | 2002 | 16 | 0.180 |
Why?
|
| Peripheral Nervous System | 1 | 2002 | 19 | 0.180 |
Why?
|
| Cardiac Glycosides | 1 | 2001 | 5 | 0.180 |
Why?
|
| Digoxin | 1 | 2001 | 21 | 0.180 |
Why?
|
| Kidney | 3 | 2015 | 1111 | 0.170 |
Why?
|
| Electric Stimulation | 5 | 2004 | 344 | 0.170 |
Why?
|
| G1 Phase | 2 | 2012 | 64 | 0.170 |
Why?
|
| In Vitro Techniques | 5 | 2003 | 948 | 0.170 |
Why?
|
| Lamiaceae | 1 | 2001 | 2 | 0.170 |
Why?
|
| Sodium Channel Blockers | 1 | 2001 | 26 | 0.170 |
Why?
|
| Analgesics, Non-Narcotic | 2 | 1998 | 51 | 0.170 |
Why?
|
| Acetaminophen | 2 | 1998 | 61 | 0.170 |
Why?
|
| Anticoagulants | 1 | 2004 | 457 | 0.170 |
Why?
|
| Pain Management | 1 | 2003 | 180 | 0.160 |
Why?
|
| Enkephalins | 2 | 1999 | 14 | 0.160 |
Why?
|
| Myocardial Contraction | 1 | 2001 | 188 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2014 | 366 | 0.160 |
Why?
|
| Gastric Mucosa | 1 | 2000 | 70 | 0.160 |
Why?
|
| North America | 2 | 2011 | 195 | 0.160 |
Why?
|
| Amphibian Venoms | 1 | 2000 | 1 | 0.160 |
Why?
|
| Cardiovascular Diseases | 1 | 2007 | 754 | 0.160 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2014 | 666 | 0.150 |
Why?
|
| Analysis of Variance | 4 | 2004 | 884 | 0.150 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2000 | 53 | 0.150 |
Why?
|
| HT29 Cells | 2 | 2009 | 49 | 0.150 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2000 | 196 | 0.150 |
Why?
|
| Reproducibility of Results | 3 | 2016 | 2715 | 0.150 |
Why?
|
| Calibration | 2 | 2014 | 106 | 0.150 |
Why?
|
| Receptors, Opioid, delta | 1 | 1999 | 7 | 0.150 |
Why?
|
| Perioperative Care | 1 | 2001 | 188 | 0.150 |
Why?
|
| Polysaccharides | 3 | 2006 | 96 | 0.150 |
Why?
|
| Time Factors | 6 | 2009 | 5410 | 0.150 |
Why?
|
| Naloxone | 3 | 2009 | 72 | 0.150 |
Why?
|
| Receptors, Opioid, kappa | 1 | 1999 | 19 | 0.150 |
Why?
|
| Endothelins | 1 | 1999 | 26 | 0.150 |
Why?
|
| Brain | 2 | 2001 | 2391 | 0.150 |
Why?
|
| GABA-A Receptor Antagonists | 1 | 1998 | 14 | 0.140 |
Why?
|
| Thrombin | 1 | 1999 | 60 | 0.140 |
Why?
|
| GABA Modulators | 1 | 1998 | 8 | 0.140 |
Why?
|
| Ion Channel Gating | 1 | 2001 | 302 | 0.140 |
Why?
|
| Gene Regulatory Networks | 2 | 2013 | 317 | 0.140 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 1998 | 86 | 0.140 |
Why?
|
| Injections, Intravenous | 4 | 2005 | 212 | 0.140 |
Why?
|
| Anti-HIV Agents | 1 | 2001 | 195 | 0.140 |
Why?
|
| Tumor Cells, Cultured | 2 | 2010 | 1028 | 0.140 |
Why?
|
| GABA Agonists | 3 | 2004 | 18 | 0.140 |
Why?
|
| Caspase 3 | 2 | 2012 | 162 | 0.130 |
Why?
|
| Arousal | 1 | 1998 | 171 | 0.130 |
Why?
|
| Sheep | 4 | 2001 | 203 | 0.130 |
Why?
|
| Medicine, Traditional | 2 | 2016 | 8 | 0.130 |
Why?
|
| Rhizome | 2 | 2009 | 7 | 0.130 |
Why?
|
| Substance P | 1 | 1997 | 62 | 0.130 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2009 | 887 | 0.120 |
Why?
|
| Cell Line | 2 | 2016 | 2464 | 0.120 |
Why?
|
| Diet, High-Fat | 1 | 2017 | 135 | 0.120 |
Why?
|
| Pyrrolidines | 1 | 1996 | 61 | 0.120 |
Why?
|
| Spectrophotometry, Ultraviolet | 2 | 2006 | 40 | 0.120 |
Why?
|
| Affect | 1 | 1998 | 396 | 0.120 |
Why?
|
| Pyridines | 2 | 2013 | 303 | 0.120 |
Why?
|
| Drug Therapy, Combination | 3 | 2009 | 759 | 0.120 |
Why?
|
| Metabolomics | 1 | 2016 | 98 | 0.120 |
Why?
|
| Insulin | 3 | 2008 | 1185 | 0.120 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2014 | 201 | 0.120 |
Why?
|
| Molecular Conformation | 1 | 2016 | 110 | 0.120 |
Why?
|
| Vacuoles | 2 | 2013 | 48 | 0.120 |
Why?
|
| Molecular Docking Simulation | 2 | 2013 | 57 | 0.110 |
Why?
|
| Models, Molecular | 3 | 2012 | 1353 | 0.110 |
Why?
|
| Analgesics | 1 | 1996 | 127 | 0.110 |
Why?
|
| Adolescent | 5 | 2016 | 9606 | 0.110 |
Why?
|
| Superoxides | 2 | 2007 | 75 | 0.110 |
Why?
|
| Blood Urea Nitrogen | 1 | 2015 | 33 | 0.110 |
Why?
|
| Opioid-Related Disorders | 1 | 1998 | 233 | 0.110 |
Why?
|
| Nitric Oxide Synthase Type III | 2 | 2009 | 83 | 0.110 |
Why?
|
| Oxonic Acid | 1 | 2014 | 8 | 0.110 |
Why?
|
| Xanthine Oxidase | 1 | 2014 | 25 | 0.110 |
Why?
|
| Discriminant Analysis | 1 | 2014 | 64 | 0.110 |
Why?
|
| Enzyme Inhibitors | 2 | 2013 | 641 | 0.110 |
Why?
|
| Electron Spin Resonance Spectroscopy | 2 | 2007 | 324 | 0.110 |
Why?
|
| Enteritis | 1 | 2014 | 23 | 0.110 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2008 | 691 | 0.110 |
Why?
|
| Malondialdehyde | 1 | 2014 | 26 | 0.110 |
Why?
|
| Glutathione Peroxidase | 1 | 2014 | 24 | 0.100 |
Why?
|
| Energy Metabolism | 2 | 2009 | 299 | 0.100 |
Why?
|
| Treatment Outcome | 5 | 2015 | 9099 | 0.100 |
Why?
|
| Feces | 1 | 2016 | 360 | 0.100 |
Why?
|
| Boraginaceae | 1 | 2013 | 3 | 0.100 |
Why?
|
| Canada | 1 | 2014 | 194 | 0.100 |
Why?
|
| Reference Standards | 1 | 2014 | 146 | 0.100 |
Why?
|
| Principal Component Analysis | 1 | 2014 | 167 | 0.100 |
Why?
|
| Naphthoquinones | 1 | 2013 | 8 | 0.100 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2016 | 291 | 0.100 |
Why?
|
| Prediabetic State | 1 | 2014 | 42 | 0.100 |
Why?
|
| Fluoresceins | 2 | 2004 | 43 | 0.100 |
Why?
|
| Ankle Joint | 1 | 2014 | 59 | 0.100 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2013 | 89 | 0.100 |
Why?
|
| Oxidation-Reduction | 2 | 2006 | 410 | 0.100 |
Why?
|
| Cyclooxygenase 2 | 1 | 2013 | 99 | 0.100 |
Why?
|
| Isoflavones | 1 | 2013 | 13 | 0.100 |
Why?
|
| Superoxide Dismutase | 1 | 2014 | 155 | 0.100 |
Why?
|
| Action Potentials | 4 | 2001 | 581 | 0.100 |
Why?
|
| Organ Size | 1 | 2014 | 362 | 0.100 |
Why?
|
| Iridoids | 1 | 2013 | 2 | 0.100 |
Why?
|
| Acupuncture Therapy | 2 | 2004 | 9 | 0.100 |
Why?
|
| S Phase Cell Cycle Checkpoints | 1 | 2013 | 3 | 0.100 |
Why?
|
| Glucose Intolerance | 1 | 2014 | 100 | 0.100 |
Why?
|
| Salvia miltiorrhiza | 1 | 2013 | 3 | 0.100 |
Why?
|
| Neoplasm Transplantation | 1 | 2014 | 399 | 0.100 |
Why?
|
| Cyclin B1 | 1 | 2013 | 16 | 0.100 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2013 | 57 | 0.100 |
Why?
|
| Thymus Gland | 1 | 2014 | 196 | 0.100 |
Why?
|
| Knee Joint | 1 | 2014 | 161 | 0.100 |
Why?
|
| Spleen | 1 | 2014 | 374 | 0.100 |
Why?
|
| Hydrogen | 3 | 1998 | 53 | 0.100 |
Why?
|
| Membrane Proteins | 2 | 2014 | 1264 | 0.100 |
Why?
|
| Acupuncture Points | 2 | 2003 | 2 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2014 | 203 | 0.100 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2013 | 165 | 0.100 |
Why?
|
| Tea | 1 | 2012 | 19 | 0.090 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2013 | 42 | 0.090 |
Why?
|
| Fasting | 2 | 2004 | 163 | 0.090 |
Why?
|
| Species Specificity | 1 | 2014 | 684 | 0.090 |
Why?
|
| Body Temperature | 2 | 2004 | 131 | 0.090 |
Why?
|
| Annexin A5 | 1 | 2012 | 20 | 0.090 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2012 | 99 | 0.090 |
Why?
|
| Microdialysis | 1 | 2012 | 23 | 0.090 |
Why?
|
| United States | 3 | 2014 | 7622 | 0.090 |
Why?
|
| Caspase 9 | 1 | 2012 | 47 | 0.090 |
Why?
|
| Enzyme Induction | 1 | 2012 | 83 | 0.090 |
Why?
|
| Sensitivity and Specificity | 2 | 2009 | 1922 | 0.090 |
Why?
|
| Biotransformation | 1 | 2011 | 46 | 0.090 |
Why?
|
| Hydrogen Bonding | 1 | 2012 | 154 | 0.090 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 985 | 0.090 |
Why?
|
| Catalytic Domain | 1 | 2012 | 163 | 0.090 |
Why?
|
| Forecasting | 2 | 2003 | 293 | 0.090 |
Why?
|
| Enzyme Activation | 3 | 2014 | 674 | 0.090 |
Why?
|
| HIV Infections | 1 | 2001 | 961 | 0.090 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2011 | 98 | 0.090 |
Why?
|
| Microscopy, Video | 2 | 2002 | 36 | 0.080 |
Why?
|
| Dietary Fats | 1 | 2011 | 135 | 0.080 |
Why?
|
| Cell Growth Processes | 1 | 2011 | 83 | 0.080 |
Why?
|
| Plant Bark | 1 | 2010 | 5 | 0.080 |
Why?
|
| Doxorubicin | 1 | 2011 | 284 | 0.080 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2010 | 101 | 0.080 |
Why?
|
| Middle Aged | 6 | 2016 | 27573 | 0.080 |
Why?
|
| Glucuronates | 1 | 2010 | 21 | 0.080 |
Why?
|
| Apigenin | 1 | 2010 | 8 | 0.080 |
Why?
|
| Down-Regulation | 1 | 2011 | 524 | 0.080 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2011 | 295 | 0.080 |
Why?
|
| Growth Inhibitors | 1 | 2009 | 41 | 0.080 |
Why?
|
| Fluorescein-5-isothiocyanate | 1 | 2009 | 27 | 0.080 |
Why?
|
| Binding Sites | 1 | 2012 | 1133 | 0.070 |
Why?
|
| Liver | 1 | 2014 | 1210 | 0.070 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2011 | 457 | 0.070 |
Why?
|
| Homeodomain Proteins | 1 | 2012 | 556 | 0.070 |
Why?
|
| Kinetics | 2 | 2002 | 1492 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 367 | 0.070 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 2009 | 56 | 0.070 |
Why?
|
| Heating | 1 | 2008 | 17 | 0.070 |
Why?
|
| Statistics, Nonparametric | 2 | 2000 | 302 | 0.070 |
Why?
|
| ErbB Receptors | 1 | 2011 | 506 | 0.070 |
Why?
|
| Intestines | 1 | 2012 | 432 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2014 | 589 | 0.070 |
Why?
|
| Cyclins | 1 | 2008 | 80 | 0.070 |
Why?
|
| Cell Membrane | 2 | 2003 | 664 | 0.070 |
Why?
|
| Enkephalin, D-Penicillamine (2,5)- | 2 | 1999 | 3 | 0.070 |
Why?
|
| 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer | 2 | 1999 | 10 | 0.070 |
Why?
|
| Pain Measurement | 2 | 2003 | 373 | 0.070 |
Why?
|
| Protein Binding | 1 | 2012 | 1534 | 0.070 |
Why?
|
| Enkephalin, Ala(2)-MePhe(4)-Gly(5)- | 2 | 1999 | 21 | 0.070 |
Why?
|
| Combined Modality Therapy | 1 | 2012 | 1723 | 0.070 |
Why?
|
| Ethanol | 1 | 2010 | 273 | 0.070 |
Why?
|
| Computer Simulation | 1 | 2012 | 1118 | 0.070 |
Why?
|
| Clinical Trials as Topic | 2 | 2005 | 1103 | 0.070 |
Why?
|
| Acetylcysteine | 2 | 2010 | 73 | 0.070 |
Why?
|
| T-Lymphocytes | 1 | 2014 | 1275 | 0.070 |
Why?
|
| Picrates | 1 | 2007 | 12 | 0.070 |
Why?
|
| Hydroxyl Radical | 1 | 2007 | 36 | 0.060 |
Why?
|
| Hydrazines | 1 | 2007 | 33 | 0.060 |
Why?
|
| CD56 Antigen | 1 | 2007 | 18 | 0.060 |
Why?
|
| Camellia sinensis | 1 | 2007 | 6 | 0.060 |
Why?
|
| Thirst | 1 | 2007 | 19 | 0.060 |
Why?
|
| Cluster Analysis | 1 | 2008 | 391 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2000 | 917 | 0.060 |
Why?
|
| Mice, Inbred BALB C | 1 | 2009 | 1101 | 0.060 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 1917 | 0.060 |
Why?
|
| Biphenyl Compounds | 1 | 2007 | 60 | 0.060 |
Why?
|
| Chlorogenic Acid | 1 | 2006 | 3 | 0.060 |
Why?
|
| Heart Ventricles | 2 | 2003 | 650 | 0.060 |
Why?
|
| Caffeic Acids | 1 | 2006 | 5 | 0.060 |
Why?
|
| Catalase | 1 | 2006 | 46 | 0.060 |
Why?
|
| Fluorescent Dyes | 2 | 2006 | 257 | 0.060 |
Why?
|
| Burns | 1 | 2008 | 149 | 0.060 |
Why?
|
| Reference Values | 2 | 1998 | 608 | 0.060 |
Why?
|
| Gene Expression Regulation | 1 | 2015 | 1985 | 0.060 |
Why?
|
| Cell Shape | 1 | 2006 | 50 | 0.060 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2012 | 826 | 0.060 |
Why?
|
| Uncoupling Agents | 1 | 2006 | 15 | 0.060 |
Why?
|
| Thymidine | 1 | 2006 | 59 | 0.060 |
Why?
|
| Drug Combinations | 1 | 2006 | 200 | 0.060 |
Why?
|
| Lung Neoplasms | 2 | 2009 | 2365 | 0.060 |
Why?
|
| Fatigue | 1 | 2007 | 181 | 0.060 |
Why?
|
| Zanthoxylum | 2 | 2016 | 9 | 0.060 |
Why?
|
| Zingiberaceae | 2 | 2016 | 10 | 0.060 |
Why?
|
| Cell Adhesion | 1 | 2006 | 416 | 0.060 |
Why?
|
| Half-Life | 1 | 2005 | 93 | 0.060 |
Why?
|
| DNA Replication | 1 | 2006 | 168 | 0.060 |
Why?
|
| Antidiarrheals | 1 | 2005 | 14 | 0.060 |
Why?
|
| Models, Animal | 1 | 2006 | 282 | 0.050 |
Why?
|
| Quality of Life | 1 | 2013 | 1780 | 0.050 |
Why?
|
| Nitric Oxide Synthase | 2 | 2009 | 123 | 0.050 |
Why?
|
| Ondansetron | 1 | 2004 | 8 | 0.050 |
Why?
|
| International Normalized Ratio | 1 | 2004 | 37 | 0.050 |
Why?
|
| Bicuculline | 1 | 2004 | 18 | 0.050 |
Why?
|
| Biofeedback, Psychology | 1 | 2004 | 13 | 0.050 |
Why?
|
| Nerve Fibers | 1 | 2004 | 40 | 0.050 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2004 | 22 | 0.050 |
Why?
|
| Microelectrodes | 1 | 2004 | 87 | 0.050 |
Why?
|
| Cats | 1 | 2004 | 285 | 0.050 |
Why?
|
| Cross-Over Studies | 1 | 2004 | 390 | 0.050 |
Why?
|
| Chickens | 1 | 2004 | 206 | 0.050 |
Why?
|
| Young Adult | 1 | 2016 | 6930 | 0.050 |
Why?
|
| Iron | 1 | 2004 | 174 | 0.050 |
Why?
|
| Axons | 1 | 2004 | 179 | 0.050 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2003 | 69 | 0.050 |
Why?
|
| Cell Size | 1 | 2003 | 71 | 0.050 |
Why?
|
| Evoked Potentials | 1 | 2004 | 194 | 0.050 |
Why?
|
| Mice, Inbred Strains | 1 | 2003 | 280 | 0.050 |
Why?
|
| Glucose Clamp Technique | 1 | 2002 | 42 | 0.050 |
Why?
|
| Asteraceae | 1 | 2002 | 4 | 0.050 |
Why?
|
| Protein Kinase C | 1 | 2003 | 261 | 0.050 |
Why?
|
| Hyperphagia | 1 | 2002 | 35 | 0.050 |
Why?
|
| Myocardial Reperfusion | 1 | 2002 | 24 | 0.050 |
Why?
|
| Hydrotherapy | 1 | 2002 | 5 | 0.050 |
Why?
|
| Neural Pathways | 1 | 2004 | 322 | 0.050 |
Why?
|
| Evidence-Based Medicine | 1 | 2005 | 449 | 0.050 |
Why?
|
| Gastrointestinal Tract | 1 | 2004 | 195 | 0.040 |
Why?
|
| DNA | 1 | 2007 | 1265 | 0.040 |
Why?
|
| Injections, Subcutaneous | 1 | 2002 | 131 | 0.040 |
Why?
|
| Garlic | 1 | 2001 | 1 | 0.040 |
Why?
|
| Echinacea | 1 | 2001 | 2 | 0.040 |
Why?
|
| Dogs | 2 | 2000 | 634 | 0.040 |
Why?
|
| Ginkgo biloba | 1 | 2001 | 7 | 0.040 |
Why?
|
| Hypericum | 1 | 2001 | 3 | 0.040 |
Why?
|
| Muscle, Skeletal | 1 | 2004 | 474 | 0.040 |
Why?
|
| Microscopy, Fluorescence | 1 | 2003 | 436 | 0.040 |
Why?
|
| Wisconsin | 1 | 2001 | 44 | 0.040 |
Why?
|
| Atropine | 1 | 2001 | 53 | 0.040 |
Why?
|
| Ethnopharmacology | 1 | 2001 | 2 | 0.040 |
Why?
|
| Potassium Channels | 1 | 2003 | 346 | 0.040 |
Why?
|
| Diet | 1 | 2004 | 460 | 0.040 |
Why?
|
| Electric Conductivity | 1 | 2001 | 142 | 0.040 |
Why?
|
| Electron Transport | 1 | 2001 | 72 | 0.040 |
Why?
|
| Receptors, Cholecystokinin | 1 | 2000 | 1 | 0.040 |
Why?
|
| Body Weight Changes | 1 | 2000 | 1 | 0.040 |
Why?
|
| Lidocaine | 1 | 2001 | 62 | 0.040 |
Why?
|
| Myocardial Ischemia | 1 | 2002 | 140 | 0.040 |
Why?
|
| Potassium | 1 | 2001 | 232 | 0.040 |
Why?
|
| Perfusion | 1 | 2002 | 260 | 0.040 |
Why?
|
| Insulin Resistance | 1 | 2003 | 379 | 0.040 |
Why?
|
| Tablets, Enteric-Coated | 1 | 2000 | 6 | 0.040 |
Why?
|
| Drug Design | 1 | 2001 | 133 | 0.040 |
Why?
|
| Phenethylamines | 1 | 2000 | 6 | 0.040 |
Why?
|
| Sodium Channels | 1 | 2001 | 130 | 0.040 |
Why?
|
| Phytosterols | 1 | 1999 | 6 | 0.040 |
Why?
|
| Lactulose | 1 | 2000 | 22 | 0.040 |
Why?
|
| Patch-Clamp Techniques | 1 | 2001 | 378 | 0.040 |
Why?
|
| Sodium | 1 | 2001 | 329 | 0.040 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2000 | 53 | 0.040 |
Why?
|
| HEK293 Cells | 2 | 2012 | 696 | 0.040 |
Why?
|
| Illinois | 1 | 2001 | 520 | 0.040 |
Why?
|
| Muscle, Smooth | 2 | 1998 | 300 | 0.040 |
Why?
|
| Transfection | 1 | 2001 | 880 | 0.040 |
Why?
|
| Nitroarginine | 1 | 1999 | 16 | 0.040 |
Why?
|
| Umbilical Cord | 1 | 1999 | 40 | 0.040 |
Why?
|
| Vagotomy | 1 | 1998 | 12 | 0.040 |
Why?
|
| Chromatography, Gas | 1 | 1998 | 27 | 0.040 |
Why?
|
| Piperidines | 1 | 2000 | 165 | 0.040 |
Why?
|
| Adjuvants, Immunologic | 1 | 1999 | 173 | 0.040 |
Why?
|
| Guinea Pigs | 2 | 1997 | 163 | 0.040 |
Why?
|
| Receptors, GABA-B | 1 | 1998 | 9 | 0.040 |
Why?
|
| Blotting, Western | 2 | 2010 | 784 | 0.040 |
Why?
|
| Receptors, GABA-A | 1 | 1998 | 34 | 0.040 |
Why?
|
| Hirschsprung Disease | 1 | 1998 | 13 | 0.030 |
Why?
|
| Cecum | 1 | 1998 | 78 | 0.030 |
Why?
|
| Muscle Contraction | 2 | 1998 | 256 | 0.030 |
Why?
|
| Gastrointestinal Agents | 1 | 2000 | 181 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 1998 | 401 | 0.030 |
Why?
|
| Sulfonamides | 1 | 2000 | 331 | 0.030 |
Why?
|
| Histamine | 1 | 1997 | 116 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 1997 | 159 | 0.030 |
Why?
|
| Pressure | 1 | 1996 | 166 | 0.030 |
Why?
|
| Aging | 1 | 1999 | 727 | 0.030 |
Why?
|
| Ubiquitinated Proteins | 1 | 2014 | 4 | 0.030 |
Why?
|
| Ileum | 1 | 1995 | 167 | 0.030 |
Why?
|
| Bcl-2-Like Protein 11 | 1 | 2014 | 25 | 0.030 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2014 | 84 | 0.030 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2014 | 41 | 0.030 |
Why?
|
| Jejunum | 1 | 2014 | 76 | 0.030 |
Why?
|
| CD3 Complex | 1 | 2014 | 135 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 254 | 0.020 |
Why?
|
| Pre-B-Cell Leukemia Transcription Factor 1 | 1 | 2012 | 5 | 0.020 |
Why?
|
| Intestine, Small | 1 | 1995 | 310 | 0.020 |
Why?
|
| Life Style | 1 | 2014 | 183 | 0.020 |
Why?
|
| Cell Culture Techniques | 1 | 2013 | 197 | 0.020 |
Why?
|
| Cell Line, Transformed | 1 | 2012 | 152 | 0.020 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2012 | 77 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2012 | 224 | 0.020 |
Why?
|
| Unfolded Protein Response | 1 | 2012 | 48 | 0.020 |
Why?
|
| Calcium | 1 | 1997 | 1176 | 0.020 |
Why?
|
| Ubiquitination | 1 | 2012 | 78 | 0.020 |
Why?
|
| Autophagy | 1 | 2014 | 172 | 0.020 |
Why?
|
| Gene Rearrangement | 1 | 2012 | 168 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2012 | 192 | 0.020 |
Why?
|
| Bone Marrow Transplantation | 1 | 2012 | 281 | 0.020 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2012 | 166 | 0.020 |
Why?
|
| DNA Fragmentation | 1 | 2011 | 65 | 0.020 |
Why?
|
| Bone Marrow Cells | 1 | 2012 | 264 | 0.020 |
Why?
|
| Heat-Shock Proteins | 1 | 2012 | 178 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2012 | 371 | 0.020 |
Why?
|
| Amino Acid Chloromethyl Ketones | 1 | 2010 | 25 | 0.020 |
Why?
|
| Caspase Inhibitors | 1 | 2010 | 32 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2012 | 555 | 0.020 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2010 | 52 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2014 | 688 | 0.020 |
Why?
|
| Grape Seed Extract | 1 | 2009 | 4 | 0.020 |
Why?
|
| Disease Progression | 1 | 2014 | 1531 | 0.020 |
Why?
|
| Peptides | 1 | 2012 | 656 | 0.020 |
Why?
|
| Protective Agents | 1 | 2009 | 34 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2011 | 1133 | 0.020 |
Why?
|
| Enteral Nutrition | 1 | 2008 | 104 | 0.020 |
Why?
|
| Bacteria | 1 | 2011 | 509 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2012 | 1234 | 0.020 |
Why?
|
| Aged | 2 | 2014 | 20434 | 0.020 |
Why?
|
| Critical Illness | 1 | 2008 | 343 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2012 | 1691 | 0.010 |
Why?
|
| Models, Biological | 1 | 2009 | 1768 | 0.010 |
Why?
|
| Mutation | 1 | 2010 | 4272 | 0.010 |
Why?
|
| Myenteric Plexus | 1 | 1998 | 1 | 0.010 |
Why?
|
| Rats, Mutant Strains | 1 | 1998 | 23 | 0.010 |
Why?
|
| Somatostatin | 1 | 1998 | 58 | 0.010 |
Why?
|
| Breeding | 1 | 1998 | 42 | 0.010 |
Why?
|
| Emetics | 1 | 1998 | 3 | 0.010 |
Why?
|
| Apomorphine | 1 | 1998 | 8 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 1998 | 293 | 0.010 |
Why?
|
| Fura-2 | 1 | 1997 | 21 | 0.010 |
Why?
|
| Drug Tolerance | 1 | 1997 | 59 | 0.010 |
Why?
|
| Pedigree | 1 | 1998 | 961 | 0.010 |
Why?
|
| Radiography | 1 | 1998 | 790 | 0.010 |
Why?
|
| Biomarkers | 1 | 1998 | 1910 | 0.010 |
Why?
|